bluebird bio Inc (BLUE) Quote

Cool, have a gr8 wkd too!!!

Buys clearing sales at 2:1 on close today. Have a relaxing weekend!

???
Although they say rev/cash won’t be affected, Nasdaq and certain requirements may cause RS, other shareholder issues, NO??
I will reload once filed!!!

On March 26, 2024, bluebird announced that it will restate its consolidated financial statements for the first three quarters and full-year 2022, as well as the first three quarters of 2023. As a result, the Company’s Annual Report Form 10-K for 2023 and its Q1 2024 Form 10-Q have been delayed. The Company is continuing to work expeditiously to complete these filings. Consistent with previous updates, the restatement is not expected to impact the Company’s cash position or revenue. Mr. Sterling will transition to oversee the restatement process upon his start date.

I have arguments.

Not until K/q’s submitted to sec.gov
This management is not trust worthy!!! Yet!!!

Seemed like a good day to buy the dip.

I encourage both of you folks to send email to blue IR/PR for update regarding financials …Funds won’t buy until compliant!!! ( prob won’t get answer, but we have no other means in which to ‘understand the delay better’)

coleary@bluebirdbio.com

Hi Courtney,
When can we expect the 10k/Q's to be filed with SEC/Edgar???
Respectfully,
Shareholder

Having been a Long Term Bull, I’m afraid management’s bravado and arrogance has caused many investors( institutional & retail) to flee the ticker!! Until they can properly file their 10K/Q’s, funds and investors will wait it out around this $1 mark..the problems that could/will arise are:
Nasdaq requirements and a ‘going concern’ in their K/Q’s when/if filed….i will add to my sizable position( north of 150k shrs in various accts) once Fins published …would not be shocked with mgmt R/S shares and do another Cap raise!! We need insider buys to feel more secure and believe in mgmts long term goals and targets/estimates..GLTA

Been sticking to the higher priced stocks this year(after being bitten badly by the inexpensive tickers for sometime, lol).BLUE is one of the few exceptions that I've let myself into. Waiting for this to shoot above the psychological $1 mark, hopefully soon.Good luck to all of us here.

That's a nice average - beats mine by a lot!! I hope you're into the long-term.

BLUE(0.973) looking good, volume/price spiked yesterday & it's been holding onto those gains today. Should be getting past the dollar mark soon. Prefer a nice steady move rather than a quick pop. Watching closely, my present avg 1.15.

Seriously? What does this have to do with the actual company?

What is Naked Short Selling?
Before we get into Naked Short Selling let’s understand the basic premises around short selling.
Short selling is the sale of a security that is not owned by the seller.
The motivation for short selling is an investor's belief that a stock's price will decline, enabling the short seller to buy the stock back in the future at a lower price and make a profit.
Normally, when one short sells a stock, their broker will lend them the shares to sell. The loaned stock will come from the broker's own inventory, from another one of the firm's customers, or from another brokerage firm. The shares are sold and the proceeds are credited to the short seller's account.
As payment for borrowing the shares, the short seller is charged a fee, quoted as an annualized percentage of the value of the loaned securities - i.e. a borrower of a stock with a 5% stock borrow rate will be charged $5 per year for every $100 of stock borrowed. Stock borrow rates change daily based in large part on the supply and demand to borrow that particular stock.
If the number of shares available to borrow is in short supply and/or great demand (which is often the case in highly shorted stocks), finding shares to borrow can be difficult and expensive.
A frequently asked question and outlined in our FAQ’s but let’s look at naked short selling from various perspectives.
How does naked short selling effect the stock market?
When a seller "naked short sells a stock" they do not own the shares they are selling and therefore are selling artificial shares. This is like counterfeiting a stock. This process creates an obvious unfair advantage to the seller and an imbalance in the market as the sell side is now increased with more shares – many of which are counterfeit. There is a time limit on how long the seller can sell these shares and be naked on the trade and the time limit is 3 days. This is where the RegSho rules come in and the data we track. If the sellers broker-dealer has not located a borrow to cover this short trade within 3 days they will need to purchase back the shares they have sold on the open market. This process is referred to as a "Buy In".
"When it comes to illicit short selling, the shorts win over 90% of the time"Naked Short – A license to steal?
Naked short selling is yet another creation of the securities industry and is in essence nothing more than a license to create counterfeit shares. When you are inflating the amount of stock that is outstanding in a company, this is considered counterfeiting. The rules justify the practice by saying it helps create smooth, efficient and orderly markets. Same stuff we have heard countless times around high-frequency trading, but in reality we believe this practice leads to shady characters creating unlimited supplies of counterfeit stocks which in turn results in your investment continuing to decline and you wondering why?
I am sure you here because you are a shareholder in a company that just continues to go down, and you have no idea why. Nothing material has happened but the trading doesn’t make any sense. We hear it all the times. Most CEO’s don’t even understand, and are baffled. The worst part is, good luck getting anyone to listen! There is a major epidemic going on right now with naked short selling right now.
It's funny when we hear CEO's say , I will just buy all the shares up and own the whole O/S and they wont be able to short me anymore. Really?
Read about: Global Links Corporation and see what happened when Robert Simpson purchased 100% of Global Link’s 1,158,064 shares. Then you will truly understand how the system is rigged. Back to counterfeiting…

We've already covered my query of your bearish to bullish flip a few months back; given the content of these posts and the time frame ($20, $18, $10, $100!), you are stead-fast super-bullish, contrary to your post and response from....February?, questioning experience and why bullish. Not to be rude, just wondering where your aces are. All I've got is 4 chips, a chair, and a belief in two things: Coincidence and Einmal ist Keinmal (Once is insignificant). I have other things, too - like substantial recognized losses, as well as substantial unrealized losses here and elsewhere. I have a bit more in our pocket that may be worth all the rest - I have a feeling that Skysona and the associated data set may hold incredible value for addressing both Alzheimers and Substance Abuse/Addiction.

I'm looking for more content like a blind man who can feel the sun. You're the only moderator. Posts should be relevant to the substance of the company - not potshots.

I Appreciate your concern for my frustrations with Mgmt, I’m use to IT seeing I’ve been investing for 53 years, took 2 companies public and graduated from a top 10 business school, and worked on Wall Street ( major IB firms) in the 80’s/90’s :)…and now retired…

However, I agree with your assertion about FDA/SEC, so we are on same page my friend..

My guess it got approved without a committee of KOL’s/Panel , etc based on the ‘earlier version’ and the changes made( that allowed for approval)

Adverse Reactions
The most common adverse reactions ≥
Grade 3 (incidence ≥ 20%) were stomatitis, thrombocytopenia,
neutropenia, febrile neutropenia, anemia, and leukopenia.
Three patients died during LYFGENIA clinical trials; one from sudden cardiac death due to underlying disease and two from acute myeloid leukemia who were treated with an….

“earlier version of LYFGENIA using a different manufacturing process and transplant procedure” (Study 1, Group A).

As you are aware, many New cell therapies have a ‘boxed warning’ that would scare the Bjesus out of a patient, but tell that to a sickle cell person and they’ll take the risk to live a ‘normal’ life vs. the The Consequences!

The fact they got Payers that cover Millions of folks is impressive, so 2nd half should provide tremendous revenue growth, we just need them to stretch cash run way ( thru better controls) and get the contract Mfg/lease issue behind them!!
File the K/ and Q’s and ambulance chasers will disappear..GLTA

I'm sorry you're frustrated, it is understandable. What is NOT understandable is why the FDA would approve lovo-cel/Lyfgenia with a Black Box warning. As I have already said, if the BB warning holds merit, the hold should never have been lifted in the first place. To be clear, THAT is where I think you should focus your frustrations - the hit job by the FDA. Any lawyers worth their salt aren't involved in this class action. IMHO.

The SEC should absolutely be investigating Dec 8 2023 stock action on CRSP and BLUE with special deference to the FDA.

Not a bad gig if you can find one like Blueballs likes to handout!! (New CFO)

(a) Base Salary. The Executive's
“base salary rate shall be $500,000 per year”

. The Executive's base salary shall be re-determined annually
by the Board or the Compensation Committee of the Board of Directors (the "Compensation Committee"). The annual base salary rate in effect at any given time is referred to herein as "Base Salary." The Executive's Base Salary shall be payable in a manner that is consistent with the Company's usual payroll practices for senior executives.
(b) Incentive Compensation. The Executive shall be eligible to receive cash incentive compensation as determined by the Board or the
Compensation Committee from time to time. The Executive's target annual incentive compensation shall be forty five percent (45%) of their Base Salary, although any the actual incentive compensation amount shall be discretionary.

(c) Equity. The Executive shall be granted: i)

an “option to purchase 300,000 shares of the Common Stock of the Company (the upuon), ii) 100,000 restricted stock units (the "RSUs"), and iii) 50,000 performance-based restricted stock units, The Option shall shares (the "PRSUs"),

which PRSUs shall be granted subject to stockholder approval of an increase to the aggregate shares authorized for issuance under the Company's 2023 Incentive Award Plan at the Company's 2024 annual meeting of stockholders. The Option shall have an exercise price equal to the closing price of the Company's common stock on the NASDAQ Global Select Market on the date of grant (the "Grant Date"), and 25% shall vest and become exercisable on the first anniversary of the Grant Date, and in equal monthly installments over the following three years, provided the Executive continues his employment through the applicate vesting date, and shall be memorialized in an Incentive Stock Option Agreement pursuant to the Company's 2021 Inducement Plan. The RSUs shall vest as follows, provided the Executive continues his employment through the applicable vesting date: 25% on the first anniversary of the Grant Date, and in three equal annual installments for the following three years on the anniversaries of the Grant Date, and shall be memorialized in a Restricted Stock Unit Agreement pursuant to the Company's 2021 Inducement Plan. The PRSUs shall vest, to the extent earned based on the achievement of certain total shareholder return performance metrics, on the third annual anniversary of the Grant Date, provided the Executive continues his employment through the vesting date. The PRSUs shall be subject to the same performance metrics as the Company's existing performance-based restricted stock units granted in 2024 and shall be memorialized in a Performance Restricted Stock Unit Agreement pursuant to the Company's 2023 Incentive Award Plan.
(d) Sign On Bonus. In addition to the Base Salary, in the event the Executive begins employment on the Start Date, the Executive will receive a one-time

“ sign on bonus in the amount of $100,000”,

less applicable taxes (the "Signing Bonus") to be paid in the first 30 days following the Start Date. If the Executive does not join the Company on the Start Date, the Executive will not receive the Signing Bonus.

It all comes down to terrible management that can’t get 10k / Q’s out on timely basis*!! Cash burn for C.Ste benefit vs. shareholders!!! CFO hopefully was fired bcuz he & auditors couldn’t get Leaseback properly journaled!!! Wall St/Analysts don’t trust CEO!!! Was never a believer in these ambulance chasers, but I will def join class action when contacted( via mail) …as for the 3 product FDA approval, I give mgmt A+ plus the payer successes…I will add once K’s/Q’s filed and figure out if CFO bailed ship due to Q2 financials are reported

"bluebird has the largest and deepest ex-vivo gene therapy data set in the field".

This class action is dark times - but it's misplaced, and it will fail, with one of the defensible factors being the removal of "multiple undisclosed" from the pipeline page. That's not a pocket-ace for the sharks, if ya follow. I feel for those that lost, and I am down also - but this is solely on the FDA, and nobody's gonna sue them, sadly. All these sharks...trying to hold Bluebird accountable for ...forward-planning and a lack of caution by analysts?? Geez...the type-set was clear.

Pretty good buy action today, IMO. I've got a little left in the tank, and I see no reason to assume 30%+ share equity increase, but baking-in the value of 2500 therapy instances on 200m is a lot to wrap. Back to top, future...................unknown.

That implies a $6b takeout , from your lips to his ears! According to your price target, 300mm* shares @ $20=$6bills

*300m estimated shares outstanding after a couple rounds of equity raise(s)

Mgmt needs to have better cash burn controls, prefer RSU’s/grants vs. cash salaries( don’t care bout restrictive dilution, cash is king for micro’s)

Gets bought above $20.00 within 18 months. No worries there imho

Irrefutable...changed my mind, had to increase the position.

BLUE 10 day hourly chart

You should post more. I have faith in Gina Wang's rating, and I also believe whether or not the first patient receiving Lyfgenia needs to have a second cell collection is going to be influential in significant ways.

Your $5 - $10 prediction for/in 2025 will require every bit of that $300 million revs confirmation and then some. In the real world this is an easy double by the end of the year at $100 million (short putt). Thankfully I have been watching it for many years and went all in based on the $1 price and recent approval of the 3rd drug. $10 is doable late late next year at best in my safety first opinion

Q1 decent rev, but we need to get thru Q3 to truly see traction of all 3 indications to assume ~$300mm in revs…cash burn better than historical run rate , but I believe the 10k/Q overhang ( analyst asked about OPEX, P&L , etc) will persist until filed..these Analyst need to model all metrics but I remain positive as we get to 2nd half, 24’ …we need more color from management in 2nd half to move the needle towards $5pps to start , then $10 is probable in 2025 imho..GLTA

Cash relatively unchanged q over q. Starts on track for 105 in 2024. Revenue over 300 million based on current metrics and pricing. Headed back to $10.00 imho

Let’s all jump on the call starting at 8am

+1 (800) 715-9871
Conference ID 9768329.

It works and it's just starting to run. Once it begins, there is no looking back

I dont think less than $18.00 will be agreed upon for starter talks to BP. BLUE has a better drug than crsp and will outpace them on many levels including speed and cell collections due to the fact vertex must do 2 to 4 collections for every patient to our 1. Bluebird can get back over $100.00 on their own with patient investors imho

Seeking Alpha must be wrong

Hmm. Coulda sworn I heard the bell. 17:34, 05.07.2024.

BLUE 10Q due after the bell per Seeking Alpha
T+1 settlement begins 5/28

There are *THREE* approved curative therapies. Adrenoleukodystrophy, Beta Thalassemia, and Sickle Cell.

IMO, this should be at least $5. But there's that word: Future. Unknown.

Money is nice. Being able to live, and live pain free - that's much nicer.

if the drug works.....can be a runner!

Easy. Each patient is 3.1 million in revenue. Do the math and it's easy to see with 20,000 patients eligible in u.s.a. alone the revenue is in the 10s of Billions over next 5 to 10 years

First Patient Begins Newly Approved Sickle Cell Gene Therapy


https://www.nytimes.com/2024/05/06/health/sickle-cell-cure-first.html

bluebird bio Announces Completion of First Cell Collection for LYFGENIA™ Gene Therapy
Published: May 06, 2024

https://www.biospace.com/article/releases/bluebird-bio-announces-completion-of-first-cell-collection-for-lyfgenia-gene-therapy/

I can only answer by pointing to one operative word in my post, and that is undefined, for no one knows what it will bring. That word is "future".

As an early childhood survivor of an Astrocytoma and a recipient of blood transfusions prior to 1983, I have significant interest in all three of their drugs - from neurological issues to blood issues. Clearly, I have no shame and am not afraid.

Some call it investing, others call it gambling. I may sell, but I am inclined it "let it ride". If I sell, it is only bc I need liquidity. As with all ventures, one should not engage unless they are willing to lose it all. I can't afford to lose it all, but I'm still here. And I am grateful for that.

Finally, the major issue to contend with is bad actors. I assure you I am not - but I can only ask that people have faith that my actions and intentions are pure of heart.

This is a very interesting stock. What is your unbiased opinion on price target for this year and 2025? The biggest fear is about cash burn rate and sustainability. How can they be cash flow positive?

I'll tell you what I think, friend - I'm eager for earnings on the 7th, although I'm fairly positive we will not see them for another few weeks after that date. I think that the class action is going to fail, that patient starts across all three drugs is going to exceed the minimum forecast of...what was it, 80 patient starts?, and that BLUE is going to skyrocket in the future, becoming the talk of wall street.

At any rate, I'm not buying anymore, even though today is/was my calendar day to avoid making wash sales. I will say that I may sell at any given point in time - the volatility is nerve racking and times are getting tight, as it were.... But much like a certain other person, I like the stock. I like the stock a LOT.

The Gross law firm has filed a class action lawsuit against Bluebird on behalf of shareholders who purchased between April 24 2023 and December 8 2023.

IMO, Blue has not committed the securities law violations alleged (which have not been named or enumerated, btw), and any lawsuit going forward should be filed against the FDA for their issuance of the "Blackbox" warning. Blue stated previously they intend to address the non-award of the PRV with the FDA. They should also be pursuing removal of the "Blackbox" warning; if the Blackbox warning had teeth, the clinical trial hold should never have been lifted in the first place - but the FDA vindicated BLUE from this previously. Furthermore, if BLUE did commit securities fraud (again, unspecified how), then that falls onto the regulatory agency moreso than BLUE, IMO.

Honestly - if not a single analyst anticipated the Blackbox warning, this is all a malignant waste of time by the FDA.

[ALLEGATIONS: According to the complaint, on December 8, 2023, Blue announced that the Food and Drug Administration (FDA) approved its drug Lyfgenia (lovotibeglogene autotemcel), also known as lovo-cel for the treatment of sickle cell disease in patients ages 12 and older who have a history of vaso-occlusive events (VOEs). However, the Lyfgenia approval came with a black box warning for haematological malignancies after two patients developed AML during the clinical trials. Analysts noted that they did not expect the black box warning or the absence of a priority review voucher. Following this news, Blue's stock price fell by $1.95 per share, or approximately 40% to close at $2.86 per share.]

That seeking alpha article is behind a paywall, unfortunately. I'm sure I wouldn't be the only happy person if you posted the sentences that you find informative.

I believe in the power of BlueBird's medicines, but I am concerned about the shorts, as I've had a ridiculous amount of calls get just completely disintegrated by the pressure on this stock in the last 2.5 years. Hopefully, we find that Blue management is honest and also correct about their projections going forward. In addition to that, I'm keeping my fingers crossed that it is Hercules's goal to help facilitate the healthcare options that BLUE has created, and not to steal the entirety of the companies I.P. The agreement does hinge somewhat on the company trading, if I am correct in my calculations, above $2.63 USD for the preceding 30 days of the first day of any financial quarter.

I've lost out significantly to other companies' management teams over the years that were malignant, and I am deeply disturbed that BLUE eliminated the graphic of "Misc Undisclosed" from their pipeline page in the summer of '23. I'm disappointed they haven't addressed that, and have significant thoughts about addressing management over the issue myself. If any of these class action examinations have solid footing, that is one aspect that will be exposed.

I will be reducing my holdings, starting next week, by ~11% for tax harvesting purposes, but I am not going anywhere. I am hoping it tanks a bit more so I can keep more than 89% of my current holdings.

I hope you got in, I think it's worth it means nothing financially on the filing they found while securing financing and going over the books. The shorts were killing it but now that Hercules is the lender they have slowed and its non-dilutive financing. Read this transcript and watch the trading action if you haven't bought in yet. You can always buy calls. https://seekingalpha.com/article/4680564-bluebird-bio-inc-blue-q4-2023-earnings-call-transcript

OK! Checking out this error that's driving the price to a discount. Is this worth grabbing? I see that it used to be very high. I made the mistake of the same thing with other bios.....

BLUE under $2

Also, if it's the last quarter results that are public, why would this not be relevant might I ask? It's pretty standard in the industry for the last posted quarter results to stay relevant untill the next quarter or year end becomes publicly available. Do you know something the market does not on why the most recent c.c. would not be relevant??

Just wondering because the fact you question this would make one think you are fairly new to the investing world, which is fine, but I like to know where you're coming from that's all 🤔🤔🤔

I have a hard time cheering someone who posts 4 month old info without a qualifier that it is 4 month old information. Couple that with your sudden appearance and flip from bearish to bullish within 3 weeks of each other....

I posted this because it was the last earnings on record. Q3 2023 results are a good indicator of growth and ramp for BLUE. The next c.c. is only weeks away for full year 2023 and fourth quarter 2023 which are normally combined into 1 earnings report and c.c.

Cheers

Nov 7, 2023 at 8:00 AM EST has long since passed.

Why did you post this?